APA (7th ed.) Citation

Heyward, W. L., Kyle, M., Blumenau, J., Davis, M., Reisinger, K., Kabongo, M. L., . . . Martin, J. T. (2013). Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine, 31(46), 5300-5305. https://doi.org/10.1016/j.vaccine.2013.05.068

Chicago Style (17th ed.) Citation

Heyward, William L., et al. "Immunogenicity and Safety of an Investigational Hepatitis B Vaccine with a Toll-like Receptor 9 Agonist Adjuvant (HBsAg-1018) Compared to a Licensed Hepatitis B Vaccine in Healthy Adults 40–70 Years of Age." Vaccine 31, no. 46 (2013): 5300-5305. https://doi.org/10.1016/j.vaccine.2013.05.068.

MLA (9th ed.) Citation

Heyward, William L., et al. "Immunogenicity and Safety of an Investigational Hepatitis B Vaccine with a Toll-like Receptor 9 Agonist Adjuvant (HBsAg-1018) Compared to a Licensed Hepatitis B Vaccine in Healthy Adults 40–70 Years of Age." Vaccine, vol. 31, no. 46, 2013, pp. 5300-5305, https://doi.org/10.1016/j.vaccine.2013.05.068.